NCT06152978 - A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma | Biotech Hunter

Enrollment

182

Participants

Timeline

Start Date

December 15, 2023

Primary Completion Date

December 15, 2025

Study Completion Date

December 15, 2027

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG

Sintilimab

Sintilimab (200mg) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.

DRUG

Chemotherapy

Cisplatin (75mg/m2) wih routine hydration for 3 days and nab-paclitaxel (260mg/m2) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

collaborator

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

lead

Fudan University

OTHER